Mim8 shows up to 98.7% reduction in annualized bleeding rate for haemophilia A.

From GlobeNewswire: 2024-06-23 01:01:17

Results from the phase 3 FRONTIER2 trial presented at ISTH 2024 showed up to 95% of people with haemophilia A, with no prior prophylactic treatment, had zero treated bleeds while on Mim8. Mim8 demonstrated a superior reduction in annualised bleeding rate (ABR) by 97.1% with once-weekly treatment and 98.7% with once-monthly treatment. The trial included 254 adults and adolescents with and without inhibitors. Mim8 is a next-generation Factor VIIIa (FVIIIa) mimetic bispecific antibody designed for prophylactic treatment of haemophilia A, with and without inhibitors. The data demonstrated the potential for zero bleeds and convenient dosing flexibility. Novo Nordisk aims to submit Mim8 for regulatory approval by the end of 2024.



Read more at GlobeNewswire: Mim8 demonstrated superior reductions in